Dechra plans an animal health manufacturing plant in East Windsor, New Jersey, where it expects to create over 100 new full-time jobs over the next decade. The veterinary specialty pharmaceuticals company announced the project Tuesday, Nov. 3, in a company release.
Dechra said the facility will support small-molecule and biologics aseptic manufacturing. It is completing readiness activities and facility upgrades now, with a target of full operations in 2028. The company did not disclose a dollar amount for the East Windsor investment in its announcement.
Key facts
| Item | What Dechra announced |
|---|---|
| Location | East Windsor, New Jersey |
| Facility | Completed in 2019 and designed to support aseptic manufacturing |
| Work planned | Small-molecule and biologics aseptic manufacturing |
| Hiring plan | Over 100 new full-time jobs in the region over the next decade |
| Roles | STEM fields and advanced-manufacturing disciplines |
| Current stage | Readiness activities and facility upgrades |
| Fully operational target | 2028, a company expectation |
| Investment amount | Not disclosed in the Nov. 3 release |
Key facts: Manufacturers Lists. All project details are company statements or plans from Dechra’s Nov. 3, 2026, release.
“Our manufacturing and supply chain capabilities must evolve alongside the business to sustain momentum on our growth journey.”
Ian MacKellar, Chief Operating Officer, Dechra, in the Nov. 3 release
Why Aseptic Manufacturing Takes More Than Factory Floor Space
Aseptic pharmaceutical production is more than making a product and putting it in a carton. Federal current good manufacturing practice regulations address facility design, material flow, environmental controls and validated procedures aimed at preventing contamination.
Under 21 CFR 211.42, aseptic processing areas require, as appropriate, smooth and easily cleanable surfaces, temperature and humidity controls, filtered air under positive pressure, environmental monitoring, and systems for cleaning, disinfecting and maintaining equipment. The same regulation addresses space and flow intended to prevent mix-ups and contamination.
A separate provision, 21 CFR 211.113, calls for written procedures designed to prevent microbiological contamination of drug products represented as sterile. Those procedures must include validation of all aseptic and sterilization processes.
Those requirements distinguish a completed building from a functioning sterile-production operation. Dechra’s release does not provide a detailed validation schedule, regulatory submission timetable or initial production date. Its disclosed milestones are the readiness and upgrade work now underway and its expectation of full operations in 2028.
A U.S. Animal Health Manufacturing Plant and Jobs Plan
Dechra describes the East Windsor investment as part of its long-term strategy to strengthen manufacturing capabilities and enhance supply-chain resilience so it can better serve people caring for animals. The company says the site will support a range of full-time roles across STEM fields and advanced-manufacturing disciplines.
That makes this a manufacturing-capacity story as well as a local employment story. The jobs are planned in New Jersey, and the proposed work is veterinary pharmaceutical production using specialized processes. But the hiring total is a long-range company projection, not a count of positions already filled. Dechra’s release gives neither a year-by-year hiring schedule nor a breakdown of individual occupations.
The supply-chain benefit is likewise the company’s stated objective, not yet a measured result of the East Windsor project. The release does not identify which existing supply routes would change, how much product the site would make or which specific medicines it would produce.
Boston Headquarters Adds Context
Dechra has also moved its global leadership base to the United States. In March, the company announced plans to relocate its global headquarters from Northwich, England, to Boston, positioning executive leadership and strategic operations closer to the North American market. Dechra announced the headquarters’ official opening on June 25.
Chief Executive Officer Jesper Nordengaard connected the two locations in the Nov. 3 announcement: “This site is a long-term investment in our global network and reflects our commitment to not only the future growth of Dechra, but to the local economy in a community close-by our new global headquarters in Boston.”
The announcements describe a company locating both leadership functions and new manufacturing infrastructure in the United States. The East Windsor plant’s job total, production timing and operating target still remain company plans rather than completed results.
What to Watch Next
- Readiness and upgrades. Watch for detailed construction, equipment, validation and initial-production milestones ahead of the 2028 full-operations target.
- Hiring. Dechra says over 100 full-time jobs over the next decade. Start dates, annual hiring totals and specific job openings have not been announced in the release.
- Investment size. The company has not disclosed the East Windsor project’s cost, annual production capacity or specific product slate.
- Public incentives. Dechra’s release does not name a tax credit, grant or other incentive award. Any future New Jersey or East Windsor government release should establish whether public incentives are part of the project.
- Supply-chain effects. Watch for the company to identify which products or supply routes the U.S. site will support. No such assignments were disclosed Nov. 3.
For more businesses in this sector, see the Manufacturers Lists pharmaceutical manufacturers list.
Comments